A
Andreas Burchert
Researcher at University of Marburg
Publications - 139
Citations - 6235
Andreas Burchert is an academic researcher from University of Marburg. The author has contributed to research in topics: Myeloid leukemia & Transplantation. The author has an hindex of 34, co-authored 117 publications receiving 5035 citations. Previous affiliations of Andreas Burchert include University of Giessen & University Medical Center Freiburg.
Papers
More filters
Journal ArticleDOI
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Robert Zeiser,Andreas Burchert,Claudia Lengerke,Mareike Verbeek,Kristina Maas-Bauer,S K Metzelder,Silvia Spoerl,Markus Ditschkowski,Matyas Ecsedi,Katja Sockel,Francis Ayuk,Salem Ajib,F.S. de Fontbrune,Il-Kang Na,Livius Penter,Udo Holtick,Dominik Wolf,Esther Schuler,Everett Meyer,Petya Apostolova,Hartmut Bertz,Reinhard Marks,Michael Lübbert,Ralph Wäsch,Christoph Scheid,Friedrich Stölzel,Rainer Ordemann,Gesine Bug,Guido Kobbe,Robert S. Negrin,Mats Brune,Alexandros Spyridonidis,Annette Schmitt-Gräff,W.J.F.M. van der Velden,Gerwin Huls,Stephan Mielke,G. U. Grigoleit,Jürgen Kuball,Ryan Flynn,Gabriele Ihorst,Jing Du,Bruce R. Blazar,Renate Arnold,Kröger N,Jakob Passweg,Jörg Halter,Gérard Socié,Dietrich W. Beelen,Christian Peschel,Andreas Neubauer,Jürgen Finke,Justus Duyster,N von Bubnoff +52 more
TL;DR: Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.
Journal ArticleDOI
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele,Johan Richter,Joelle Guilhot,Franz Gruber,Henrik Hjorth-Hansen,Antonio Almeida,Jeroen Janssen,Jiri Mayer,Perttu Koskenvesa,Panayiotis Panayiotidis,Ulla Olsson-Strömberg,Joaquin Martinez-Lopez,Philippe Rousselot,Hanne Vestergaard,Hans Ehrencrona,Veli Kairisto,Katerina Machova Polakova,Martin Müller,Satu Mustjoki,Marc G. Berger,Alice Fabarius,Wolf-Karsten Hofmann,Andreas Hochhaus,Markus Pfirrmann,Francois-Xavier Mahon,Gert J. Ossenkoppele,Maria Pagoni,Stina Söderlund,Martine Escoffre-Barbe,Gabriel Etienne,Jolanta Dengler,Françoise Huguet,Nikolas von Bubnoff,Hana Klamova,Edgar Faber,François Guilhot,Kourosh Lotfi,Delphine Rea,Tim H. Brümmendorf,Gorgine E. de Greef,Leif Stenke,Franck E. Nicolini,Laurence Legros,Andreas Burchert,Jaroslava Voglová,Aude Charbonnier,Emmanuel Gyan,Volker Kunzmann,Peter E. Westerweel +48 more
TL;DR: In this paper, a prospective, non-randomised trial was conducted at 61 European centres in 11 countries to investigate the impact of stopping TKI therapy on the survival of patients with chronic myeloid leukaemia.
Journal ArticleDOI
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Nicolaus Kröger,Ernst Holler,Guido Kobbe,Martin Bornhäuser,Rainer Schwerdtfeger,Herrad Baurmann,Arnon Nagler,Wolfgang Bethge,Matthias Stelljes,Lutz Uharek,Hannes Wandt,Andreas Burchert,Paolo Corradini,Jörg Schubert,Martin Kaufmann,Peter Dreger,Gerald Wulf,Hermann Einsele,Tatjana Zabelina,Hans Michael Kvasnicka,Jürgen Thiele,Ronald Brand,Axel R. Zander,Dietger Niederwieser,Theo de Witte +24 more
TL;DR: A prospective multicenter phase 2 trial to determine efficacy of a busulfan-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors found that age older than 55 years and human leukocyte antigen-mismatched donor remained significant factors for survival.
Journal ArticleDOI
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Röllig,Hubert Serve,Andreas Hüttmann,Richard Noppeney,Carsten Müller-Tidow,Utz Krug,Claudia D. Baldus,Christian Brandts,Volker Kunzmann,Hermann Einsele,Alwin Krämer,Kerstin Schäfer-Eckart,Andreas Neubauer,Andreas Burchert,Aristoteles Giagounidis,Stefan W. Krause,Andreas Mackensen,Walter E. Aulitzky,Regina Herbst,Mathias Hänel,Alexander Kiani,Norbert Frickhofen,Johannes Kullmer,Ulrich Kaiser,Hartmut Link,Thomas Geer,A. Reichle,Christian Junghanß,Roland Repp,Frank Heits,Heinz Dürk,Jana Hase,Ina-Maria Klut,Thomas Illmer,Martin Bornhäuser,Markus Schaich,Stefani Parmentier,Martin Görner,Christian Thiede,Malte von Bonin,Johannes Schetelig,Michael Kramer,Wolfgang E. Berdel,Gerhard Ehninger +43 more
TL;DR: This randomised, double-blind, placebo-controlled, phase 2 trial investigated the efficacy and tolerability of sorafenib versus placebo in addition to standard chemotherapy in patients with acute myeloid leukaemia aged 60 years or younger.
Journal ArticleDOI
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
Andreas Burchert,Gesine Bug,Lea V. Fritz,Jürgen Finke,Matthias Stelljes,Christoph Röllig,Ellen Wollmer,Ralph Wäsch,Martin Bornhäuser,Tobias Berg,Fabian Lang,Gerhard Ehninger,Hubert Serve,Robert Zeiser,Eva-Maria Wagner,Nicolaus Kröger,Christine Wolschke,Michael Schleuning,Katharina Götze,Christoph Schmid,Martina Crysandt,Eva Eßeling,Dominik Wolf,Ying Wang,Alexandra Böhm,Christian Thiede,Torsten Haferlach,Christian Michel,Wolfgang Bethge,Thomas Wündisch,Christian Brandts,Susanne Harnisch,Michael Wittenberg,Heinz-Gert Hoeffkes,Susanne Rospleszcz,Alexander Burchardt,Andreas Neubauer,Markus Brugger,Konstantin Strauch,Konstantin Strauch,Carmen Schade-Brittinger,S K Metzelder +41 more
TL;DR: Exploratory data show that patients with undetectable minimal residual disease (MRD) before HCT and those with detectable MRD after HCT derive the strongest benefit from sorafenib, and maintenance therapy reduces the risk of relapse and death after H CT for FLT3-ITD-positive AML.